BELLUS Health (TSE:BLU) Shares Up 8.5%

BELLUS Health Inc (TSE:BLU)’s share price shot up 8.5% on Tuesday . The stock traded as high as C$3.18 and last traded at C$3.18, 359,910 shares were traded during trading. An increase of 103% from the average session volume of 177,665 shares. The stock had previously closed at C$2.93.

The company has a quick ratio of 13.65, a current ratio of 13.87 and a debt-to-equity ratio of 0.26. The stock has a market capitalization of $459.66 million and a PE ratio of -32.28. The business has a 50 day moving average price of C$2.15.

BELLUS Health (TSE:BLU) last issued its quarterly earnings data on Wednesday, May 8th. The company reported C($0.03) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of C($0.02) by C($0.01). The business had revenue of C$0.01 million for the quarter, compared to analysts’ expectations of C$0.01 million. On average, sell-side analysts expect that BELLUS Health Inc will post -0.11 EPS for the current year.

In related news, Director Franklin Milan Berger purchased 50,000 shares of the firm’s stock in a transaction dated Thursday, June 20th. The shares were acquired at an average cost of C$2.70 per share, with a total value of C$134,925.00. Following the completion of the purchase, the director now directly owns 1,502,108 shares of the company’s stock, valued at C$4,053,438.44. Also, Director Francesco Bellini purchased 31,600 shares of the firm’s stock in a transaction dated Tuesday, April 30th. The shares were bought at an average cost of C$1.14 per share, for a total transaction of C$36,024.00. Following the completion of the purchase, the director now directly owns 725,489 shares of the company’s stock, valued at C$827,057.46.

BELLUS Health Company Profile (TSE:BLU)

BELLUS Health Inc, a clinical-stage biopharmaceutical company, develops novel therapeutics for conditions with high unmet medical need. Its lead drug candidate includes BLU-5937, a small molecule antagonist of the P2X3 receptor for chronic cough. The company also has economic interests in various partnered development stage programs, including KIACTA for the treatment of sarcoidosis; AMO-01 for treatment of Phelan McDermid syndrome; and ALZ-801 for APOE4 homozygous Alzheimer's disease.

Featured Article: The Role of a Fiduciary and Individual Investors

Receive News & Ratings for BELLUS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BELLUS Health and related companies with's FREE daily email newsletter.